Navigation Links
Medicinal products susceptible to 'dose dumping' should be fully tested
Date:9/23/2009

Controlled release pills and capsules that show a tendency in the standard laboratory test toward "dose dumping" releasing their medicine in a faster and potentially unsafe manner in patients who have consumed alcohol should be withheld from the market until proven safe with testing in people. That's the conclusion of a review of existing studies in the September-October issue of ACS' Molecular Pharmaceutics, a bi-monthly journal.

In the article, Hans Lennerns analyzed the gastrointestinal factors that may contribute to dose dumping when a vulnerable formulation interacts with alcohol present in the stomach. However, these factors are highly variable and depend on individual drinking behavior, whether food is present in the stomach, and other circumstances. That makes it "almost impossible" to predict whether a patient will experience an overdose as a result of dose dumping.

Lennerns thus concludes that when laboratory testing of a product indicates that the drug will be released more quickly than intended, the product also should be tested in humans, or it should be re-formulated. Indeed, Lennerns believes that lab testing over a two hour period in a range of alcohol strengths is an "absolute minimum standard" in screening for dose dumping because products with a problem in the lab may also be dangerous to patients. Lennerns cites as an example a formulation of the pain medication hydromorphone, which was removed from the U.S. market when testing revealed that alcohol intake caused the risk of overdose. He noted, however, that there is currently a generic oxycodone product on the market in the European Union which will "most likely" lead to dose dumping in patients.


'/>"/>

Contact: Michael Woods
m_woods@acs.org
202-872-6293
American Chemical Society
Source:Eurekalert  

Page: 1

Related medicine news :

1. Medithrive Announces the Grand Opening of Its San Francisco Medicinal Marijuana Dispensary
2. Pharoahs Wine Jar Yields Medicinal Secrets
3. BioRelix and Dalton Medicinal Chemistry Expand and Renew Research Agreement to Capitalize on Riboswitches
4. European Committee for Human Medicinal Products (CHMP) Issues Positive Opinion for Once-Daily PREZISTA(R) (Darunavir) as Part of Combination Therapy for Treatment-Naive Adults With HIV-1
5. Medicinal Marijuana Eases Neuropathic Pain in HIV
6. Dr. Richard M. Soll Joined WuXi PharmaTech (NYSE: WX) as VP of Medicinal Chemistry
7. MS drug development agreement based on WEHIs medicinal chemistry
8. An Alternative to Medicinal Marijuana
9. Oriental Medicinal Herb Garden Dedication
10. Indian medicinal plant Acanthus ilicifolius may combat liver cancer
11. ATIR Classified as "Cell Based" Medicinal Product by the EMEA
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Medicinal products susceptible to 'dose dumping' should be fully tested
(Date:4/28/2017)... ... 28, 2017 , ... Children and adolescents who enter the ... children in the general population. That’s because foster care is designed to protect ... While no fault of their own, youth who have experienced trauma often have ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... could substantially improve drug safety and minimize the cost of development. In this ... channel inhibition using cell lines and for cardiac toxicity using induced pluripotent stem ...
(Date:4/28/2017)... Abilene, Texas (PRWEB) , ... April 28, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... says, reveals which name the Creator responds to and which He does not. Yisrayl ... to believe which one is the true name, but he says with a little Scripture, ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... the Brooke Grove Foundation implement a Microsoft Dynamics GP solution that integrates to ... ERP expert that specializes in long-term care, Brooke Grove now has the capability ...
(Date:4/28/2017)... ... April 28, 2017 , ... Rob Lowe is a ... he has leant his presence to an educational purpose as the host of the ... one being cancer. In a recent episode, the series focuses on thyroid cancer. , ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017   ZappRx, Inc ., ... specialty drug prescribing process, today announced it closed $25 million ... a venture capital firm based in Seattle ... Qiming Venture Partners . The Series B round included participation ... round in 2014, and GV (formerly Google Ventures). ...
(Date:4/20/2017)... LUND, Sweden , April 20, 2017 /PRNewswire/ ... OTCQX: NEVPF) ("NeuroVive") today announced positive preclinical ... company,s preclinical compound for non-alcoholic steatohepatitis (NASH), ... NV556 has previously ... STAM™ NASH model. Today, NeuroVive,s scientists present ...
(Date:4/19/2017)... 2017 The Mobile X-Ray product segment is the ... during the forecast period Mobile X-Ray segment is ... mobile X-Ray devices market, which is estimated to be valued ... a CAGR of 7% over the forecast period. Mobile X-Ray ... than US$ 100 Mn in 2017 over 2016. The segment,s ...
Breaking Medicine Technology: